Kieu Thuy Tran

US Patent:

20130039898, Feb 14, 2013

Filed:

Feb 3, 2011

Appl. No.:

13/576625

Inventors:

Augustus O. Okhamafe - Concord CA, US
Sean M. Bell - Novato CA, US
G. Nick Zecherle - Novato CA, US
Kris Antonsen - San Rafael CA, US
Yanhong Zhang - San Rafael CA, US
Kieu Ly Tran - San Francisco CA, US
Paul A. Fitzpatrick - Berkeley CA, US
Emil D. Kakkis - Novato CA, US
Michel Claude Vellard - San Rafael CA, US
Daniel J. Wendt - Walnut Creek CA, US
Mubarack Muthalif - Novato CA, US

Assignee:

BIOMARIN PHARMACEUTICAL INC. - NOVATO CA

International Classification:

A61K 38/51
A61P 3/00
A61P 7/00
C12N 9/88

US Classification:

424 945, 435232

Abstract:

Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.

US Patent:

20190345475, Nov 14, 2019

Filed:

Jan 11, 2019

Appl. No.:

16/246300

Inventors:

- Novato CA, US
Sean M. Bell - Novato CA, US
G. Nick Zecherle - Novato CA, US
Kris Antonsen - San Rafael CA, US
Yanhong Zhang - San Rafael CA, US
Kieu Ly Tran - San Francisco CA, US
Paul A. Fitzpatrick - Berkeley CA, US
Emil D. Kakkis - San Rafael CA, US
Michel Claude Vellard - San Rafael CA, US
Daniel J. Wendt - Walnut Creek CA, US
Mubarack Muthalif - Novato CA, US

Assignee:

BIOMARIN PHARMACEUTICAL INC. - Novato CA

International Classification:

C12N 9/88
A61K 47/60
A61K 9/00
C07K 1/14
A61K 38/51

Abstract:

Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.

US Patent:

20160362675, Dec 15, 2016

Filed:

Apr 15, 2016

Appl. No.:

15/130694

Inventors:

- Novato CA, US
Sean M. Bell - Novato CA, US
G. Nick Zecherle - Novato CA, US
Kris Antonsen - San Rafael CA, US
Yanhong Zhang - San Rafael CA, US
Kieu Ly Tran - San Francisco CA, US
Paul A. Fitzpatrick - Berkeley CA, US
Emil D. Kakkis - San Rafael CA, US
Michel Claude Vellard - San Rafael CA, US
Daniel J. Wendt - Walnut Creek CA, US
Mubarack Muthalif - Novato CA, US

International Classification:

C12N 9/88
A61K 47/48
A61K 38/51

Abstract:

Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.